2019
Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses
Ali ZA, Nef H, Escaned J, Werner N, Banning AP, Hill JM, De Bruyne B, Montorfano M, Lefevre T, Stone GW, Crowley A, Matsumura M, Maehara A, Lansky AJ, Fajadet J, Di Mario C. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. Circulation Cardiovascular Interventions 2019, 12: e008434. PMID: 31553205, DOI: 10.1161/circinterventions.119.008434.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac CatheterizationCoronary AngiographyCoronary StenosisEuropeFemaleHumansLithotripsyMaleMiddle AgedPatient SafetyPercutaneous Coronary InterventionProspective StudiesRisk FactorsSeverity of Illness IndexStentsTime FactorsTomography, Optical CoherenceTreatment OutcomeUnited StatesVascular CalcificationConceptsSevere coronary artery calcificationCoronary artery calcificationMajor adverse cardiac eventsAdverse cardiac eventsPrimary end pointIntravascular lithotripsyOptical coherence tomographyCardiac eventsStent implantationPlaque fractureHospital major adverse cardiac eventsNon-Q-wave myocardial infarctionOptical coherence tomography substudyIndependent clinical events committeeCoherence tomographyDrug-eluting stent implantationEnd pointCoronary intravascular lithotripsyClinical events committeeHigh procedural successIndependent core laboratoryAcute luminal gainPost-approval studiesMechanism of actionCalcium fracture
2006
Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors
Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, Lansky AJ, Mehran R. Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors. The American Journal Of Cardiology 2006, 99: 202-207. PMID: 17223419, DOI: 10.1016/j.amjcard.2006.07.084.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyPrimary percutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsAcute myocardial infarctionPercutaneous coronary interventionHeparin usePostprocedural heparinCoronary interventionMyocardial infarctionHospital major adverse cardiac eventsPrimary PCIMajor adverse cardiac eventsUnfractionated heparin infusionAdverse cardiac eventsOutcomes of patientsSubset of patientsTransluminal coronary angioplastyLate MACEPostprocedure courseHeparin infusionCardiac eventsCoronary angioplastyCoronary stentingSevere bleeding
2002
New-Device Angioplasty in Women: Clinical Outcome and Predictors in a 7,372-Patient Registry
Lansky AJ, Mehran R, Dangas G, Desai K, Costantini-Ortiz C, Cristea E, New G, Negoita M, Stone GW, Leon MB. New-Device Angioplasty in Women: Clinical Outcome and Predictors in a 7,372-Patient Registry. Epidemiology 2002, 13: s46-s51. PMID: 12071484, DOI: 10.1097/00001648-200205001-00010.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsNew device angioplastyClinical outcomesFemale genderHospital mortalityLate mortalityIndependent predictorsMortality rateHospital major adverse cardiac eventsIschemic coronary artery diseaseLong-term clinical outcomesSaphenous vein graft lesionsMultivariable logistic regression analysisDevice-specific outcomesHospital cardiac mortalityLate clinical outcomesAdverse cardiac eventsComorbid risk factorsCongestive heart failureNative coronary arteriesOutcomes of womenVein graft lesionsCoronary artery diseaseReference vessel sizeConventional balloon angioplasty